Abstract
The design, synthesis, and structure-activity relationships of a new class of potent and orally active non-peptide dipeptidyl peptidase IV (DPP-4) inhibitors, 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones, are described. We hypothesized that the 4-phenyl group of the isoquinolone occupies the S1 pocket of the enzyme, the 3-aminomethyl group forms an electrostatic interaction with the S2 pocket, and the introduction of a hydrogen bond donor onto the 6- or 7-substituent provides interaction with the hydrophilic region of the enzyme. Based on this hypothesis, intensive research focused on developing new non-peptide DPP-4 inhibitors has been carried out. Among the compounds designed in this study, we identified 2-[(3-aminomethyl-2-(2-methylpropyl)-1-oxo-4-phenyl-1,2-dihydro-6-isoquinolinyl)oxy]acetamide (35a) as a potent, selective, and orally bioavailable DPP-4 inhibitor, which exhibited in vivo efficacy in diabetic model rats. Finally, X-ray crystallography of 35a in a complex with the enzyme validated our hypothesized binding mode and identified Lys554 as a new target-binding site available for DPP-4 inhibitors.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Administration, Oral
-
Animals
-
Blood Glucose
-
Caco-2 Cells
-
Diabetes Mellitus, Type 2 / drug therapy
-
Dipeptidyl Peptidase 4 / analysis
-
Dipeptidyl Peptidase 4 / drug effects*
-
Dipeptidyl-Peptidase IV Inhibitors / administration & dosage
-
Dipeptidyl-Peptidase IV Inhibitors / chemical synthesis*
-
Dipeptidyl-Peptidase IV Inhibitors / chemistry
-
Dipeptidyl-Peptidase IV Inhibitors / pharmacology
-
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
-
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / analysis
-
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / antagonists & inhibitors
-
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / drug effects
-
Drug Design
-
Female
-
Glucose Tolerance Test
-
Humans
-
Hypoglycemic Agents / administration & dosage
-
Hypoglycemic Agents / chemical synthesis*
-
Hypoglycemic Agents / chemistry
-
Hypoglycemic Agents / pharmacology
-
Hypoglycemic Agents / therapeutic use
-
Isoquinolines / administration & dosage
-
Isoquinolines / chemical synthesis*
-
Isoquinolines / pharmacology
-
Isoquinolines / therapeutic use
-
Molecular Targeted Therapy
-
Peptides / metabolism
-
Quinolones / administration & dosage
-
Quinolones / chemical synthesis
-
Quinolones / chemistry
-
Quinolones / pharmacology
-
Quinolones / therapeutic use
-
Rats
-
Rats, Wistar
-
Structure-Activity Relationship
Substances
-
2-((3-(aminomethyl)-2-(2-methylpropyl)-1-oxo-4-phenyl-1,2-dihydroisoquinolin-6-yl)oxy)acetamide
-
Blood Glucose
-
Dipeptidyl-Peptidase IV Inhibitors
-
Hypoglycemic Agents
-
Isoquinolines
-
Peptides
-
Quinolones
-
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
-
dipeptidyl peptidase II
-
Dipeptidyl Peptidase 4